Protein Production Services and Solutions

Published: septembre 8, 2026

Recombinant protein production services integrate automated liquid handling, clone selection, cell culture optimization, protein expression, purification, and analytical testing into a unified workflow, supporting laboratories to improve reproducibility, accelerate timelines, and enhance data quality.

Key Takeaways

  • Protein production services integrate automation, clone selection, cell culture optimization, protein expression, purification, and analytical testing.
  • End-to-end solutions help improve reproducibility, accelerate development timelines, and enhance data quality.
  • Automation and high-throughput screening support streamlined workflows from gene cloning to protein characterization.
  • Integrated technology platforms reduce manual intervention while increasing throughput and process scalability. 

End-to-End Protein Production Solutions

End-to-end protein production solutions for recombinant protein manufacturers combine automation, high-throughput screening, and advanced analytics to streamline the entire workflow from gene cloning to protein characterization.

Platforms such as the Biomek i-Series Automated Liquid Handlers and Echo Acoustic Liquid Handlers support automated sample preparation, assay setup, and workflow standardization, while systems such as the BioLector XT Microbioreactor and Cydem VT Automated Clone Screening System enable rapid clone screening, cultivation optimization, and process development. Together, these technologies create a data-driven, scalable protein production workflow that reduces manual intervention, increases throughput, and supports faster, more informed decision-making throughout the protein development lifecycle.

View References
  1. Alhammad LA, Ainosah TK, Ahmad AM et al. (2023). The impact of laboratory automation on efficiency and accuracy in healthcare settings. International Journal Of Community Medicine And Public Health, 11(1), 459–463.
  2. Bhatwa A, Wang W, Hassan YI et al. (2021). Challenges Associated With the Formation of Recombinant Protein Inclusion Bodies in Escherichia coli and Strategies to Address Them for Industrial Applications. Frontiers in Bioengineering and Biotechnology. 9:630551.
  3. Blass E, Ott PA. (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature Reviews Clinical Oncology. 18, 215–229.
  4. Cha H, Park J-H. (2021). Recombinant Human Erythropoietin Production in Chinese Hamster Ovary Cells Is Enhanced by Supplementation of α-Helix Domain of 30Kc19 Protein. Applied Sciences. 11(22):11009.
  5. Chabot et al. (2026). Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins. Journal of Biological Chemistry. Volume 302(1).
  6. Chen Y-L, Xie X-X, Zhong N et al. (2023). Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies. International Journal of Molecular Sciences. 24(5):4307.
  7. Creangă EC, Stan R, Nicolae AC et al. (2025). Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications. Pharmaceutics. 17(9):1190.
  8. Echelard Y, Meade HM, Ziomek CA. (2006). Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals. BioPharm International. 19(8).
  9. Gupta V, Sengupta M, Prakash J et al. (2017). Production of Recombinant Pharmaceutical Proteins. In: Basic and Applied Aspects of Biotechnology. Springer, Singapore.
  10. Gupta V et al. (2016). Production of Recombinant Pharmaceutical Proteins. Basic and Applied Aspects of Biotechnology. 77–101.
  11. Hernandez SI, Berezin CT, Miller KM et al. (2024). Sequencing Strategy to Ensure Accurate Plasmid Assembly. ACS Synthetic Biology. 13(12):4099-4109.
  12. Hong M, Li T, Xue W et al. (2022). Genetic engineering of baculovirus-insect cell system to improve protein production. Frontiers in Bioengineering and Biotechnology. 10:994743.
  13. Hou L, Zhang XY, Li Y et al. (2016). Rapid Screening of Recombinant Plasmids by Direct Colony Quantitative Real-Time PCR. Advances in Bioscience and Biotechnology. 7, 428-433.
  14. Beckman Coulter. Nanoliter-Scale DNA Assembly with the Echo 525 Liquid Handler Application Note.
  15. Jayakrishnan A, Wan Rosli WR, Tahir ARM et al. (2024). Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review. Sci. 6(1):9.
  16. Kumar V, Barwal A, Sharma N et al. (2024). Therapeutic proteins: developments, progress, challenges, and future perspectives. 3 Biotech. 14, 112.
  17. Mahmood F, Xu R, Awan MUN et al. (2023). HBV Vaccines: Advances and Development. Vaccines. 11(12):1862.
  18. Martins JT, Bourbon AI, Pinheiro AC et al. (2018). Protein-Based Structures for Food Applications: From Macro to Nanoscale. Frontiers in Sustainable Food Systems. 2:77.
  19. Ojima-Kato T. (2025). Advances in recombinant protein production in microorganisms and functional peptide tags. Bioscience, Biotechnology, and Biochemistry. 89(1).
  20. Pastores GM. (2010). Recombinant Glucocerebrosidase (Imiglucerase) as a Therapy for Gaucher Disease. BioDrugs. 24, 41–47.
  21. Rosano GL, Morales ES, Ceccarelli EA. (2019). New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Science. 28(8):1412-1422.
  22. Shanmugaraj B, Bulaon CJI, Phoolcharoen W. (2020). Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants. 9(7):842.
  23. Shilling PJ, Mirzadeh K, Cumming AJ et al. (2020). Improved designs for pET expression plasmids increase protein production yield in Escherichia coli. Communications Biology. 3, 214.
  24. Wang W. (2015). Advanced protein formulations. Protein Science. 24(7):1031-9.
  25. Wu et al. (2025). Automating an Adeno-associated Virus (AAV) Functional Assay Using the Biomek i7 Liquid Handler with Integrated Vi-CELL BLU Analyzer. Application Note.
  26. Swain SM, Shastry M, Hamilton E. (2023). Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery. 22(2):101-126.
  27. Konkle B, Oldenburg J, Pasi J et al. (2023). Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
  28. Gao Y, Yin Y, Xie P et al. (2025). Interferon in Liver Diseases: Recent Advances. Advances in Therapy. 42, 4210–4223.

Explore Related Protein Production Topics

Continue exploring the technologies, workflows, and applications that support efficient and scalable recombinant protein production.

Protein Production Workflow and Process for Life Sciences

Gain an overview of protein production workflows, expression platforms, and scalable manufacturing approaches.

View protein production overview

Challenges in Protein Production and How to Overcome Them

Identify common protein expression challenges, including low yield, aggregation, instability, and host-cell limitations, and explore strategies to improve protein quality and reproducibility.

Explore protein production solutions

Applications of Recombinant Protein Production

See how recombinant proteins are used across therapeutics, biopharmaceuticals, diagnostics, research, and biotechnology.

Explore protein applications

Automation and High-Throughput Protein Production

Learn how laboratory automation supports reproducible protein workflows, improves throughput, and accelerates process development.

Discover automation solutions

Recombinant Protein Production Workflow

Understand the complete protein production landscape, including expression systems, production workflows, and scalable manufacturing strategies.

Explore the workflow

FAQ on Protein Production Services and Solutions

When should you choose in-house protein production versus outsourcing or production services?

In-house protein production is ideal when you need greater control over protocols, rapid optimization, and protection of intellectual property. Outsourcing is often preferred for projects requiring specialized expertise, large-scale production, advanced technologies, or faster access to manufacturing capacity.

A hybrid approach is commonly used, with early-stage research performed in-house and scale-up, purification, or specialized testing outsourced to experienced service providers.

Basse Hofzumahaus 

Basse Hofzumahaus 

Product Marketing Manager 

About the author:

Basse Hofzumahaus brings 15+ years of experience in life sciences, across academia, R&D, and product management. With a PhD and M.Sc. in Biotechnology, he connects scientific depth with a focus on upstream bioprocessing, microbial fermentation, CHO workflows, clone screening, and microbioreactor development. 

Talk to an Expert